Novel pyrrolone-fused benzosuberene MK2 inhibitors: synthesis, pharmacophore modelling, molecular docking, and anti-cancer efficacy evaluation in HNSCC cells
Authors:
- YaminiYAYamini
- 11 October 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (21) , 11954-11975
Abstract
Head and neck Squamous Cell Carcinoma (HNSCC) is a growing concern worldwide and MAPKAPK2/MK2 (Mitogen-Activated Protein Kinase Activated Protein Kinase 2) is crucially involved in HNSCC progression. Increased disease burden and lacuna of targeted therapies require novel and safe pharmacological inhibitors to suppress the well-explored molecular targets in HNSCC. Here, we used dibromo-substituted benzosuberene synthesized from the mixture of α, β, γ-himachalenes and utilized as a precursor for the synthesis of Pyrrolone-fused benzosuberenes (PfBS) as MK2 inhibitors through aminocarbonylation approach in a single-pot reaction. The devised protocol provides a broad substrate scope, facile recovery, recyclability of Polystyrene-supported palladium (Pd@PS) nanoparticle catalyst, and fewer synthesis steps. In-silico molecular docking, pharmacophore modeling, and ADMET revealed MK2-inhibitory potential and drug-likeliness of PfBS analogues. Surface plasmon resonance (SPR) analysis revealed effective high binding affinity (KD) and kinetics of PfBS analogues with MK2. Additionally, the SPR-mediated in-solution inhibition assay established the MK2-inhibition properties of PfBS analogues through abrogation of MK2-Hsp27 interaction. Further, in-vitro studies validate the findings in HNSCC cells. PfBS analogues exhibited significant anti-proliferative effects on CAL 27 tongue squamous carcinoma cells and were found safe on IEC-6 intestinal epithelial cells. Moreover, immunofluorescence analysis and western-blot assays potentiated, that selected analogues inhibited the inflammatory cytokine TNF-α induced activation of MK2 on cellular and molecular levels in HNSCC cells. In conclusion, this study presents novel MK2-inhibitors and opens the avenue for further pre-clinical and clinical efficacy evaluation of developed PfBS analogues in the treatment of HNSCC.Communicated by Ramaswamy H. Sarma.Keywords
Funding Information
- Council of Scientific and Industrial Research, India
This publication has 55 references indexed in Scilit:
- Computational targeting of allosteric site of MEK1 by quinoline‐based moleculesCell Biochemistry and Function, 2022
- Mitogen‐activated protein kinase‐activated protein kinase‐2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancerMolecular Carcinogenesis, 2021
- Cancer statistics for the year 2020: An overviewInternational Journal of Cancer, 2021
- Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylation- regulated kinaseComputer Methods and Programs in Biomedicine, 2020
- Inhibition of MK2 suppresses IL‐1β, IL‐6, and TNF‐α‐dependent colorectal cancer growthInternational Journal of Cancer, 2017
- Oxalic Acid as Sustainable CO Source for Pyrrolone‐Fused Benzosuberenes Synthesis through Palladium Catalyzed Carbonylative CyclizationChemistrySelect, 2017
- Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitorsBioorganic & Medicinal Chemistry Letters, 2012
- In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part IBioorganic & Medicinal Chemistry Letters, 2010
- Drug–target residence time: critical information for lead optimizationCurrent Opinion in Chemical Biology, 2010
- Benzothiophene inhibitors of MK2. Part 1: Structure–activity relationships, assessments of selectivity and cellular potencyBioorganic & Medicinal Chemistry Letters, 2009